Astellas Hits Walls In Fending Off Prograf Generics; Options Limited
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Astellas' last ditch efforts to prevent the launch of Sandoz' generic Prograf (tacrolimus) failed last week, and as the company "evaluates its next course of action" for its top-selling product, its options do not look promising
You may also be interested in...
Japan Grants Astellas' Prograf Approval For Additional Indication Myasthenia Gravis
TOKYO - Astellas' immunosuppressant for organ transplant Prograf (tacrolimus) was granted an additional indication approval by Japan's Ministry for Health, Labor and Welfare for myasthenia gravis, an autoimmune disorder characterized by muscle weakness and fatigue, the company reported Oct. 16
Japan Grants Astellas' Prograf Approval For Additional Indication Myasthenia Gravis
TOKYO - Astellas' immunosuppressant for organ transplant Prograf (tacrolimus) was granted an additional indication approval by Japan's Ministry for Health, Labor and Welfare for myasthenia gravis, an autoimmune disorder characterized by muscle weakness and fatigue, the company reported Oct. 16
Facing Patent Losses, Astellas Funds Genome Laboratory And Reorganizes Drug Discovery Functions
Astellas announced Sept. 1 it established the Genome Medical Science Laboratory at the University of Tokyo. The laboratory is looking to elucidate the mechanism of tumorigenesis through a large analysis of clinical samples using genomics technologies to develop new cancer treatments